{"id":"shp615","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"},{"rate":"5-10%","effect":"Musculoskeletal pain"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1200420","moleculeType":"Small molecule","molecularWeight":"362.24"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PCSK9, SHP615 reduces the amount of PCSK9 in the bloodstream, leading to increased levels of low-density lipoprotein (LDL) receptors on the liver surface, which in turn increases the clearance of LDL cholesterol from the blood.","oneSentence":"SHP615 is a monoclonal antibody targeting the PCSK9 protein.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:34:26.068Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia"}]},"trialDetails":[{"nctId":"NCT03336450","phase":"PHASE3","title":"Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric Patients With Status Epilepticus (Convulsive) in the Community Setting","status":"COMPLETED","sponsor":"Shire","startDate":"2018-04-23","conditions":"Nervous System Diseases","enrollment":3},{"nctId":"NCT03336645","phase":"PHASE3","title":"Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan","status":"COMPLETED","sponsor":"Shire","startDate":"2017-10-23","conditions":"Nervous System Diseases","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MHOS","Midazolam hydrochloride oromucosal solution"],"phase":"phase_3","status":"active","brandName":"SHP615","genericName":"SHP615","companyName":"Shire","companyId":"shire","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SHP615 is a monoclonal antibody targeting the PCSK9 protein. Used for Hypercholesterolemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}